Skip to content
DataLookout
Menu

NCT06966700

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 58 versions: 50 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 335 → 338 locations
  2. Minor Trial sites expanded: 331 → 335 locations
    • Publications expanded, about 61 words
  3. Minor Trial sites expanded: 325 → 331 locations
  4. Minor Study sites: 325 to 326
  5. Notable Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 7 of 13 entries
    • Site details revised at 19 of 325 sites
  6. Minor Trial sites expanded: 321 → 325 locationsv53
  7. Minor Study sites revised (321)v52
  8. Minor Site contacts updated at 1 of 321 sitesv51
  9. Minor Study sites: 319 to 321v50
  10. Minor Study sites revised (319)v49
  11. Minor Study sites: 318 to 319v48
  12. Minor Study sites: 317 to 318v47
  13. Minor Study sites: 315 to 317v46
  14. Minor Study sites: 314 to 315v45
  15. Minor Trial sites expanded: 310 → 314 locationsv44
  16. Minor Trial sites expanded: 307 → 310 locationsv43
  17. Minor Trial sites expanded: 304 → 307 locations
    • Trial sites expanded: 296 → 304 locations
    v42
  18. Minor Study sites: 296 to 304v41
  19. Minor Study sites: 294 to 296v40
  20. Minor Study sites: 292 to 294v39
  21. Minor Study sites: 291 to 292v38
  22. Minor Trial sites expanded: 287 → 291 locationsv37
  23. Minor Trial sites expanded: 283 → 287 locationsv36
  24. Notable Eligibility criteria expanded, about 22 words
    • Trial sites expanded: 268 → 283 locations
    v35
  25. Minor Trial sites expanded: 265 → 268 locationsv34
  26. Minor Trial sites expanded: 254 → 265 locationsv33
  27. Minor Trial sites expanded: 249 → 254 locationsv32
  28. Minor Trial sites expanded: 241 → 249 locationsv31
  29. Minor Study sites: 234 to 241v30
  30. Minor Study sites: 215 to 234v29
  31. Minor Study sites: 206 to 215v28
  32. Minor Study sites: 200 to 206v27
  33. Minor Study sites: 193 to 200v26
  34. Minor Study sites: 185 to 193v25
  35. Minor Study sites: 180 to 185v24
  36. Minor Study sites: 173 to 180v23
  37. Minor Study sites: 169 to 173v22
  38. Minor Study sites: 166 to 169v21
  39. Minor Study sites: 158 to 166v20
  40. Minor Study sites: 151 to 158v19
  41. Minor Study sites: 144 to 151v18
  42. Minor Study sites: 134 to 144v17
  43. Minor Study sites: 120 to 134v16
  44. Minor Study sites: 92 to 120v15
  45. Minor Study sites: 84 to 92v14
  46. Minor Study sites: 78 to 84v13
  47. Minor Study sites: 58 to 78v12
  48. Minor Study sites: 41 to 58
    • Study completion date: Feb 4, 2035 to Dec 29, 2034
    v11
  49. Minor Study sites: 34 to 41v10
  50. Minor Study sites: 24 to 34v9
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of Participants with Pathological Complete Response (pCR) at the Time of Definitive Surgery
Timeframe: Up to approximately 30 weeks
Event-Free Survival (EFS)
Timeframe: Up to approximately 92 months

Secondary (13)

Overall Survival (OS)
Percentage of Participants with pCR with No Ductal Carcinoma in Situ (pCR-no DCIS) at the Time of Definitive Surgery
Percentage of Participants with pCR at the Time of Definitive Surgery (High-risk, early-stage, TNBC subset)
Event-Free Survival (EFS) (High-risk, early-stage, TNBC subset)
Overall Survival (OS) (High-risk, early-stage, TNBC subset)
Show 8 moreShow less
Distant Progression or Distant Recurrence-Free Survival (DPDRFS)
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status-Quality of Life Score
Change from Baseline in EORTC QLQ-C30 Physical Functioning Score
Change from Baseline in EORTC QLQ-C30 Role Functioning Score
Change from Baseline in EORTC QLQ-C30 Fatigue Score
Change from Baseline in EORTC QLQ Breast Cancer 42 (BR42) Systemic Therapy Side Effects Score
Number of Participants Who Experience One or More Adverse Events (AEs)
Number of Participants Who Discontinue Study Treatment Due to an AE

Arms and interventions

sac-TMTExperimental

Participants receive sacituzumab tirumotecan intravenously (IV) at a dose of 4 mg/kg every 2 weeks (Q2W) + IV pembrolizumab 200 mg every 3 weeks (Q3W), for 12 weeks; then receive IV pembrolizumab 200 mg Q3W and IV carboplatin area under the curve (AUC) 1.5 + IV paclitaxel 80 mg/m\^2 once weekly, for 12 weeks. 3-6 weeks later, participants undergo surgery and optional radiation therapy, and receive IV pembrolizumab 400 mg once every 6 weeks or 200 mg Q3W for up to approximately 28 weeks. Additional adjuvant treatment of physician's choice (TPC) may be administered to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline breast cancer susceptibility gene mutation (gBRCAm) only); capecitabine 1000-1250 mg/m\^2 oral twice daily on days 1-14 and 22-35 each cycle for 4 six-week cycles; or doxorubicin 60mg/m\^2 (or epirubicin 90 mg/m\^2) IV infusion Q3W/Q2W + cyclophosphamide 600 mg/m\^2 IV infusion Q3W/Q2W for 4 doses.

ChemotherapyActive comparator

Participants receive IV carboplatin AUC 1.5 and paclitaxel 80 mg/m\^2 once weekly, alongside pembrolizumab 200 mg Q3W, for 6 weeks; then receive IV pembrolizumab 200 mg Q3W alongside IV cyclophosphamide 600 mg/m\^2 Q3W and either doxorubicin 60 mg/m\^2 Q3W or epirubicin 90 mg/m\^2 Q3W, for up to 12 weeks. 3-6 weeks later, participants undergo surgery and optional radiation therapy, and receive IV pembrolizumab 400 mg once every 6 weeks or 200 mg Q3W for up to approximately 28 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options are olaparib 300 mg oral BID for 1 year (participants with germline breast cancer susceptibility gene mutation (gBRCAm) only); or capecitabine 1000-1250 mg/m\^2 oral BID on days 1-14 and 22-35 each cycle for 4 six-week cycles.

Biologicals: Sacituzumab tirumotecan, Pembrolizumab

Drugs: Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib

Sites

338 sites in 41 countries

United States 64, China 30, Japan 22, Canada 16, Italy 12, Brazil 10, Poland 10, Spain 10, United Kingdom 10, Argentina 9, France 9, Turkey (Türkiye) 9, South Korea 8, Peru 7, Colombia 6, Germany 6, Guatemala 6, Belgium 5, Greece 5, Hungary 5, India 5, Malaysia 5, Romania 5, South Africa 5, Taiwan 5, Ukraine 5, Australia 4, Chile 4, Czechia 4, Hong Kong 4, Israel 4, Norway 4, Portugal 4, Sweden 4, Thailand 4, Vietnam 4, Finland 3, New Zealand 2, Philippines 2, Saudi Arabia 1, Singapore 1